Related Experiment Video
Updated: May 11, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Systemic inflammatory response syndrome in tissue-type plasminogen activator-treated patients is associated with
Amelia K Boehme1, Niren Kapoor, Karen C Albright
1Stroke Center, Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-6810, USA.
Background And Purpose:
Systemic inflammatory response syndrome (SIRS) is a generalized inflammatory state. The primary goal of the study was to determine whether differences exist in outcomes in SIRS and non-SIRS intravenous tissue-type plasminogen activator-treated patients.
Methods:
Consecutive patients were retrospectively reviewed for the evidence of SIRS during their admission. SIRS was defined as the presence of ≥2 of the following: body temperature<36°C or >38°C, heart rate>90, respiratory rate>20, and white blood cells<4000/mm or >12 000 mm, or >10% bands. Patients diagnosed with infection (via positive culture) were excluded.
Results:
Of the 241 patients, 44 had evidence of SIRS (18%). Adjusting for pre-tissue-type plasminogen activator National Institutes of Health Stroke Scale, age, and race, SIRS remained a predictor of poor functional outcome at discharge (odds ratio [OR], 2.58; 95% confidence interval [CI], 1.16-5.73; P=0.0197).
Conclusions:
In our sample of tissue-type plasminogen activator-treated (tPA) patients, ~1 in 5 patients developed SIRS. Furthermore, we found the presence of SIRS to be associated with poor short-term functional outcomes and prolonged length of stay.
Related Concept Videos
Acute Inflammation II: Local and Systemic Effects
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Venous Thrombosis III: Interprofessional Care
Secondary Spinal Cord Injury llI: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology

